A phase IIa, randomized, two-arm parallel group, placebo-controlled, double-blind, multi-center trial (The FRACTAL Trial) is currently underway to evaluate the safety and myocardial protection of CX3CL1 inhibitors (KAND567) in myocardial infarction, and it is possible that CX3CL1/CX3CR1 targeted therapies will become available in clinical practice [93] (Table 2). Here, CX3CL1 is linked to myocardial infarction.